Koers NicOx SA Euronext Paris
Aandelen
NCOX
FR0000074130
Farmaceutische producten
Omzet 2023 | 4,2 mln. 4,51 mln. | Omzet 2024 * | 9,2 mln. 9,88 mln. | Marktkapitalisatie | 18,95 mln. 20,36 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | -15 mln. -16,11 mln. | Nettowinst (verlies) 2024 * | -14 mln. -15,04 mln. | EV/omzet 2023 | 5,25 x |
Nettoschuld 2023 * | 9,24 mln. 9,92 mln. | Nettoliquiditeiten 2024 * | - 0 | EV/omzet 2024 * | 2,06 x |
K/w-verhouding 2023 * |
-1,26
x | K/w-verhouding 2024 * |
-1,58
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 93,38% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gavin M. Spencer
CEO | Chief Executive Officer | 53 | 01-01-05 |
Michele Garufi
FOU | Founder | 70 | 15-02-96 |
Sandrine Gestin
DFI | Director of Finance/CFO | 56 | 01-01-99 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Les Kaplan
BRD | Director/Board Member | 73 | 01-10-14 |
Director/Board Member | 65 | 18-05-17 | |
Adrienne Graves
BRD | Director/Board Member | 69 | 08-08-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+6,52% | 71,94 mld. | |
+11,54% | 9,27 mld. | |
-11,55% | 5,13 mld. | |
+48,05% | 4,66 mld. | |
+5,09% | 3,97 mld. | |
-14,74% | 2,55 mld. | |
+20,00% | 2,41 mld. | |
-24,89% | 2,36 mld. | |
+21,45% | 2,21 mld. |